AmberCRO Vice President and CEO/President participated in BIO Europe 2009 conference in Vienna 2-4 November 2009.

---

AmberCRO is moving to the new office, new address: Daugavas 38/1, Marupes pag, Riga region, LV-2167, Latvia.

---

 AmberCRO Vice President and CEO had met with Tajikistan health care leaders on the 11-13 of July 2009 and agreement come in force between AmberCRO and Tajikistan responsible persons about supervising, submitting documents for Clinical Trials to the Tajikistan authorities by AmberCRO in Tajikistan.

Clinical Trials in Tajikistan.

• Motivation from the government side to allow performing Clinical trials in Tajikistan
• Motivation for doctors to take part into Clinical Trials
• Motivation for patients to participate into Clinical Trials (there are ~ 7 million inhabitants in Tajikistan)

---

AmberCRO together with the Collaboration partner will assist your company in determining key aspects of study design such as:

• Number and types of arms

• Sample size

• Randomization design

• Endpoints

• Interim analysis (superiority, futility, classic adaptive and Bayesian design, etc)

•  Adaptive elements (classical, group-sequential, Bayesian, etc.)

---